Western blot analysis showed that the expression level of FBXO22 in the tumor group was significantly higher than that in the non-tumor liver group (30 of 50 cases) (Fig. 7c and Additional file 4: Figure S4, respectively). This evidence concerns the gene FBXO22 and neoplasm.